Sign In
Buy TVGN
$9.06
+0.590 (+6.97%)
At Close: Jun 03, 2026
Why Is Tevogen Bio (TVGN) Stock Up 46% Today?
10:12am, Thursday, 04'th Apr 2024
Tevogen Bio (NASDAQ: TVGN ) stock is seeing a surprising amount of movement on Thursday after the clinical-stage biotechnology company announced a new Head of Investor Relations and Corporate Developm
Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development
08:05am, Wednesday, 03'rd Apr 2024
WARREN, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc (‘Tevogen Bio') (Nasdaq: TVGN), a clinical-stage biotech company, announces the appointment of Tapan V Shah as Head of Inves
Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price
08:05am, Thursday, 28'th Mar 2024
The shares of Series A-1 Preferred Stock will be issued in the first quarter and will be convertible at a conversion price of $10.00, as opposed to the $4.
Tevogen Bio Announces Series A-1 Preferred Stock Investment
09:20am, Wednesday, 27'th Mar 2024
The shares of Series A-1 Preferred Stock will be issued in the first quarter and will be convertible at a conversion price of $10.00, as opposed to the $4.
Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant
07:00am, Wednesday, 20'th Mar 2024
WARREN, N.J.--(BUSINESS WIRE)--Tevogen Bio Holdings ('Tevogen Bio') (Nasdaq: TVGN), today announced TVGN 489, its investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes (CTLs) imm
WARREN, N.J.--(BUSINESS WIRE)--Tevogen Bio Holdings ('Tevogen Bio') (Nasdaq: TVGN), congratulates Victor Sordillo PE, CSP, MBA, on his recent appointment as Managing Director of Risk Advisory Services
WARREN, N.J.--(BUSINESS WIRE)--Tevogen Bio Holdings – Tevogen (Nasdaq: TVGN) Chief Information Officer and Head of company's Artificial Intelligence Initiative, Tevogen.ai, Mittul Mehta, has taken s
WARREN, N.J.--(BUSINESS WIRE)--Tevogen Bio Holdings Inc. ('Tevogen Bio') (Nasdaq: TVGN) Tevogen's ExacTcell platform was developed to harness the killing ability of naturally occurring cytotoxic T lym
WARREN, N.J.--(BUSINESS WIRE)--Tevogen Bio Holdings Inc. ('Tevogen Bio') (Nasdaq: TVGN) celebrated commencement of its public trading by ringing the opening bell at the Nasdaq Stock Exchange in Times
Tevogen Bio Announces $8 Million Equity Investment
09:25am, Thursday, 15'th Feb 2024
WARREN, N.J.--(BUSINESS WIRE)--On February 14, 2024, Tevogen Bio Holdings Inc. (the “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, ge
